PAREXEL Intl Corp. (NASDAQ: PRXL) Stock Competitors & Peer Comparison
See PRXL's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for PRXL and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| PRXL | $88.08 | +0.00% | 0 | 42.97 | $2.05 | N/A |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.63% |
| TMO | $673.78 | -0.18% | 250.9B | 29.30 | $23.16 | +0.27% |
| DHR | $224.27 | -0.10% | 159.9B | 28.50 | $7.98 | +0.63% |
| NTRA | $412.74 | +0.04% | 59B | -311.95 | -$1.32 | N/A |
| A | $174.65 | +1.07% | 49.5B | 30.15 | $5.81 | +0.58% |
| IQV | $268.29 | -0.77% | 44.6B | 22.32 | $12.13 | N/A |
| WAT | $441.05 | +1.73% | 43.5B | 32.38 | $13.68 | N/A |
| IDXX | $529.82 | +2.03% | 41.7B | 37.21 | $14.22 | N/A |
| ILMN | $268.69 | -0.49% | 41.1B | 54.06 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
PRXL vs DHR-PB Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to DHR-PB. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
PRXL vs TMO Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, TMO has a market cap of 250.9B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while TMO trades at $673.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas TMO's P/E ratio is 29.30. In terms of profitability, PRXL's ROE is +0.17%, compared to TMO's ROE of +0.13%. Regarding short-term risk, PRXL is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
PRXL vs DHR Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR has a market cap of 159.9B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while DHR trades at $224.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas DHR's P/E ratio is 28.50. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check DHR's competition here
Natera, Inc. (NASDAQ: NTRA)
PRXL vs NTRA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NTRA has a market cap of 59B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NTRA trades at $412.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NTRA's P/E ratio is -311.95. In terms of profitability, PRXL's ROE is +0.17%, compared to NTRA's ROE of -0.12%. Regarding short-term risk, PRXL is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NTRA's competition here
Agilent Technologies, Inc. (NYSE: A)
PRXL vs A Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, A has a market cap of 49.5B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while A trades at $174.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas A's P/E ratio is 30.15. In terms of profitability, PRXL's ROE is +0.17%, compared to A's ROE of +0.20%. Regarding short-term risk, PRXL is less volatile compared to A. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check A's competition here
IQVIA Holdings Inc. (NYSE: IQV)
PRXL vs IQV Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, IQV has a market cap of 44.6B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while IQV trades at $268.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas IQV's P/E ratio is 22.32. In terms of profitability, PRXL's ROE is +0.17%, compared to IQV's ROE of +0.22%. Regarding short-term risk, PRXL is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check IQV's competition here
Waters Corporation (NYSE: WAT)
PRXL vs WAT Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, WAT has a market cap of 43.5B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while WAT trades at $441.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas WAT's P/E ratio is 32.38. In terms of profitability, PRXL's ROE is +0.17%, compared to WAT's ROE of +0.02%. Regarding short-term risk, PRXL is less volatile compared to WAT. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check WAT's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
PRXL vs IDXX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, IDXX has a market cap of 41.7B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while IDXX trades at $529.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas IDXX's P/E ratio is 37.21. In terms of profitability, PRXL's ROE is +0.17%, compared to IDXX's ROE of +0.72%. Regarding short-term risk, PRXL is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check IDXX's competition here
Illumina, Inc. (NASDAQ: ILMN)
PRXL vs ILMN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ILMN has a market cap of 41.1B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ILMN trades at $268.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ILMN's P/E ratio is 54.06. In terms of profitability, PRXL's ROE is +0.17%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, PRXL is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check ILMN's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
PRXL vs MTD Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MTD has a market cap of 31.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MTD trades at $1,527.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MTD's P/E ratio is 35.50. In terms of profitability, PRXL's ROE is +0.17%, compared to MTD's ROE of -12.00%. Regarding short-term risk, PRXL is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MTD's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
PRXL vs DGX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DGX has a market cap of 26.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while DGX trades at $233.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas DGX's P/E ratio is 23.44. In terms of profitability, PRXL's ROE is +0.17%, compared to DGX's ROE of +0.14%. Regarding short-term risk, PRXL is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check DGX's competition here
Labcorp Holdings Inc. (NYSE: LH)
PRXL vs LH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LH has a market cap of 25.4B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while LH trades at $308.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas LH's P/E ratio is 18.37. In terms of profitability, PRXL's ROE is +0.17%, compared to LH's ROE of +0.12%. Regarding short-term risk, PRXL is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check LH's competition here
Guardant Health, Inc. (NASDAQ: GH)
PRXL vs GH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GH has a market cap of 23.8B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while GH trades at $176.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas GH's P/E ratio is -50.81. In terms of profitability, PRXL's ROE is +0.17%, compared to GH's ROE of +2.11%. Regarding short-term risk, PRXL is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
PRXL vs EXAS Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas EXAS's P/E ratio is -95.37. In terms of profitability, PRXL's ROE is +0.17%, compared to EXAS's ROE of -0.09%. Regarding short-term risk, PRXL is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
PRXL vs MEDP Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MEDP has a market cap of 17.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MEDP trades at $620.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MEDP's P/E ratio is 36.10. In terms of profitability, PRXL's ROE is +0.17%, compared to MEDP's ROE of +1.10%. Regarding short-term risk, PRXL is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MEDP's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
PRXL vs ILMNV Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ILMNV's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to ILMNV's ROE of N/A. Regarding short-term risk, PRXL is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check ILMNV's competition here
Revvity, Inc. (NYSE: RVTY)
PRXL vs RVTY Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, RVTY has a market cap of 16.8B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while RVTY trades at $150.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas RVTY's P/E ratio is 28.22. In terms of profitability, PRXL's ROE is +0.17%, compared to RVTY's ROE of +0.03%. Regarding short-term risk, PRXL is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check RVTY's competition here
PerkinElmer, Inc. (NYSE: PKI)
PRXL vs PKI Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas PKI's P/E ratio is 41.45. In terms of profitability, PRXL's ROE is +0.17%, compared to PKI's ROE of +0.03%. Regarding short-term risk, PRXL is less volatile compared to PKI. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check PKI's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
PRXL vs CRL Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CRL has a market cap of 14.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CRL trades at $290.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CRL's P/E ratio is 29.77. In terms of profitability, PRXL's ROE is +0.17%, compared to CRL's ROE of -0.08%. Regarding short-term risk, PRXL is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
PRXL vs ICLR Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ICLR has a market cap of 13.4B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ICLR trades at $171.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ICLR's P/E ratio is 14.32. In terms of profitability, PRXL's ROE is +0.17%, compared to ICLR's ROE of +0.04%. Regarding short-term risk, PRXL is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check ICLR's competition here
Qiagen N.V. (NYSE: QGEN)
PRXL vs QGEN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, QGEN has a market cap of 9.3B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while QGEN trades at $44.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas QGEN's P/E ratio is 18.60. In terms of profitability, PRXL's ROE is +0.17%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, PRXL is less volatile compared to QGEN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check QGEN's competition here
GRAIL Inc. (NASDAQ: GRAL)
PRXL vs GRAL Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GRAL has a market cap of 5.7B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while GRAL trades at $133.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas GRAL's P/E ratio is -13.60. In terms of profitability, PRXL's ROE is +0.17%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, PRXL is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check GRAL's competition here
RadNet, Inc. (NASDAQ: RDNT)
PRXL vs RDNT Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, RDNT has a market cap of 5.6B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while RDNT trades at $70.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas RDNT's P/E ratio is 156.11. In terms of profitability, PRXL's ROE is +0.17%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, PRXL is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check RDNT's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
PRXL vs BLLN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BLLN has a market cap of 5.6B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BLLN trades at $121.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BLLN's P/E ratio is 173.89. In terms of profitability, PRXL's ROE is +0.17%, compared to BLLN's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
PRXL vs SHC Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SHC has a market cap of 5.3B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while SHC trades at $18.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas SHC's P/E ratio is 19.22. In terms of profitability, PRXL's ROE is +0.17%, compared to SHC's ROE of +0.27%. Regarding short-term risk, PRXL is less volatile compared to SHC. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
PRXL vs SYNH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas SYNH's P/E ratio is 61.40. In terms of profitability, PRXL's ROE is +0.17%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to SYNH. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check SYNH's competition here
Veracyte, Inc. (NASDAQ: VCYT)
PRXL vs VCYT Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, VCYT has a market cap of 3.6B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while VCYT trades at $45.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas VCYT's P/E ratio is 22.62. In terms of profitability, PRXL's ROE is +0.17%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, PRXL is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check VCYT's competition here
CareDx, Inc (NASDAQ: CDNA)
PRXL vs CDNA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CDNA has a market cap of 3.3B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CDNA trades at $63.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CDNA's P/E ratio is 76.90. In terms of profitability, PRXL's ROE is +0.17%, compared to CDNA's ROE of +0.33%. Regarding short-term risk, PRXL is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
PRXL vs OLK Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas OLK's P/E ratio is -96.59. In terms of profitability, PRXL's ROE is +0.17%, compared to OLK's ROE of -0.07%. Regarding short-term risk, PRXL is less volatile compared to OLK. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check OLK's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
PRXL vs WGS Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, WGS has a market cap of 2.6B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while WGS trades at $78.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas WGS's P/E ratio is 238.69. In terms of profitability, PRXL's ROE is +0.17%, compared to WGS's ROE of -0.39%. Regarding short-term risk, PRXL is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
PRXL vs PSNL Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while PSNL trades at $16.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas PSNL's P/E ratio is -14.97. In terms of profitability, PRXL's ROE is +0.17%, compared to PSNL's ROE of -0.46%. Regarding short-term risk, PRXL is less volatile compared to PSNL. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
PRXL vs OPK Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OPK has a market cap of 1.2B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while OPK trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas OPK's P/E ratio is -6.04. In terms of profitability, PRXL's ROE is +0.17%, compared to OPK's ROE of -0.06%. Regarding short-term risk, PRXL is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
PRXL vs CSTL Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CSTL has a market cap of 1.1B. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CSTL trades at $34.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CSTL's P/E ratio is -54.44. In terms of profitability, PRXL's ROE is +0.17%, compared to CSTL's ROE of -0.04%. Regarding short-term risk, PRXL is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
PRXL vs FLGT Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, FLGT has a market cap of 635M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while FLGT trades at $22.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas FLGT's P/E ratio is 2236.00. In terms of profitability, PRXL's ROE is +0.17%, compared to FLGT's ROE of -0.08%. Regarding short-term risk, PRXL is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
PRXL vs GRALV Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas GRALV's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to GRALV's ROE of N/A. Regarding short-term risk, PRXL is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check GRALV's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
PRXL vs NEO Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NEO has a market cap of 495.7M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NEO trades at $18.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NEO's P/E ratio is 148.38. In terms of profitability, PRXL's ROE is +0.17%, compared to NEO's ROE of -0.06%. Regarding short-term risk, PRXL is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NEO's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
PRXL vs MYGN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MYGN has a market cap of 400.5M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MYGN trades at $4.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MYGN's P/E ratio is -32.62. In terms of profitability, PRXL's ROE is +0.17%, compared to MYGN's ROE of -0.33%. Regarding short-term risk, PRXL is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
PRXL vs CO Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CO's P/E ratio is 5.06. In terms of profitability, PRXL's ROE is +0.17%, compared to CO's ROE of +0.11%. Regarding short-term risk, PRXL is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
PRXL vs FLDM Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas FLDM's P/E ratio is -4.74. In terms of profitability, PRXL's ROE is +0.17%, compared to FLDM's ROE of +0.18%. Regarding short-term risk, PRXL is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check FLDM's competition here
Biodesix, Inc. (NASDAQ: BDSX)
PRXL vs BDSX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BDSX has a market cap of 247.6M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BDSX trades at $29.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BDSX's P/E ratio is -9.60. In terms of profitability, PRXL's ROE is +0.17%, compared to BDSX's ROE of -7.88%. Regarding short-term risk, PRXL is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BDSX's competition here
Exagen Inc. (NASDAQ: XGN)
PRXL vs XGN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, XGN has a market cap of 204.9M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while XGN trades at $8.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas XGN's P/E ratio is -10.47. In terms of profitability, PRXL's ROE is +0.17%, compared to XGN's ROE of -1.22%. Regarding short-term risk, PRXL is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check XGN's competition here
Freenome, Inc. (NASDAQ: FRNM)
PRXL vs FRNM Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, FRNM has a market cap of 132.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while FRNM trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas FRNM's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to FRNM's ROE of N/A. Regarding short-term risk, PRXL is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check FRNM's competition here
Genetron Holdings Limited (NASDAQ: GTH)
PRXL vs GTH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas GTH's P/E ratio is -1.11. In terms of profitability, PRXL's ROE is +0.17%, compared to GTH's ROE of -1.01%. Regarding short-term risk, PRXL is less volatile compared to GTH. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
PRXL vs GENE Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas GENE's P/E ratio is -38.25. In terms of profitability, PRXL's ROE is +0.17%, compared to GENE's ROE of -1.85%. Regarding short-term risk, PRXL is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check GENE's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
PRXL vs IMDX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, IMDX has a market cap of 102.7M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while IMDX trades at $3.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas IMDX's P/E ratio is -2.13. In terms of profitability, PRXL's ROE is +0.17%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, PRXL is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check IMDX's competition here
Sera Prognostics, Inc. (NASDAQ: SERA)
PRXL vs SERA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SERA has a market cap of 77.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while SERA trades at $2.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas SERA's P/E ratio is -3.11. In terms of profitability, PRXL's ROE is +0.17%, compared to SERA's ROE of -0.47%. Regarding short-term risk, PRXL is less volatile compared to SERA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check SERA's competition here
Precipio, Inc. (NASDAQ: PRPO)
PRXL vs PRPO Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PRPO has a market cap of 43M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while PRPO trades at $23.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas PRPO's P/E ratio is -37.09. In terms of profitability, PRXL's ROE is +0.17%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, PRXL is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check PRPO's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
PRXL vs QUCY Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, QUCY has a market cap of 31.2M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while QUCY trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas QUCY's P/E ratio is -0.06. In terms of profitability, PRXL's ROE is +0.17%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, PRXL is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check QUCY's competition here
MDxHealth S.A. (NASDAQ: MDXH)
PRXL vs MDXH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MDXH has a market cap of 28.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MDXH trades at $0.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MDXH's P/E ratio is -0.75. In terms of profitability, PRXL's ROE is +0.17%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, PRXL is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MDXH's competition here
Akumin Inc. (NASDAQ: AKU)
PRXL vs AKU Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas AKU's P/E ratio is -0.13. In terms of profitability, PRXL's ROE is +0.17%, compared to AKU's ROE of -5.32%. Regarding short-term risk, PRXL is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check AKU's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
PRXL vs BNR Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BNR has a market cap of 18.6M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BNR trades at $17.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BNR's P/E ratio is -20.26. In terms of profitability, PRXL's ROE is +0.17%, compared to BNR's ROE of -0.13%. Regarding short-term risk, PRXL is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BNR's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
PRXL vs CEMI Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CEMI's P/E ratio is -0.63. In terms of profitability, PRXL's ROE is +0.17%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, PRXL is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
PRXL vs ENZ Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ENZ's P/E ratio is -2.24. In terms of profitability, PRXL's ROE is +0.17%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, PRXL is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check ENZ's competition here
Psychemedics Corporation (NASDAQ: PMD)
PRXL vs PMD Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas PMD's P/E ratio is -5.24. In terms of profitability, PRXL's ROE is +0.17%, compared to PMD's ROE of -0.32%. Regarding short-term risk, PRXL is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
PRXL vs ME Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ME's P/E ratio is -0.03. In terms of profitability, PRXL's ROE is +0.17%, compared to ME's ROE of -42.03%. Regarding short-term risk, PRXL is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check ME's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
PRXL vs MYNZ Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MYNZ's P/E ratio is -0.68. In terms of profitability, PRXL's ROE is +0.17%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, PRXL is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MYNZ's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
PRXL vs CHEK Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CHEK's P/E ratio is -0.43. In terms of profitability, PRXL's ROE is +0.17%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, PRXL is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CHEK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
PRXL vs BIAFW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIAFW has a market cap of 9.8M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BIAFW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BIAFW's P/E ratio is 1.04. In terms of profitability, PRXL's ROE is +0.17%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, PRXL is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BIAFW's competition here
Centogene N.V. (NASDAQ: CNTG)
PRXL vs CNTG Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CNTG's P/E ratio is -0.23. In terms of profitability, PRXL's ROE is +0.17%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, PRXL is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check CNTG's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
PRXL vs ADVB Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ADVB has a market cap of 9.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ADVB trades at $6.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ADVB's P/E ratio is -61.18. In terms of profitability, PRXL's ROE is +0.17%, compared to ADVB's ROE of -0.21%. Regarding short-term risk, PRXL is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check ADVB's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
PRXL vs NDRA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NDRA has a market cap of 7.5M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NDRA trades at $5.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NDRA's P/E ratio is -0.88. In terms of profitability, PRXL's ROE is +0.17%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, PRXL is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NDRA's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
PRXL vs APDN Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas APDN's P/E ratio is -0.10. In terms of profitability, PRXL's ROE is +0.17%, compared to APDN's ROE of -7.23%. Regarding short-term risk, PRXL is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check APDN's competition here
Invitae Corporation (NYSE: NVTA)
PRXL vs NVTA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NVTA's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, PRXL is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
PRXL vs LMDXW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, PRXL is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
PRXL vs LMDX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas LMDX's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, PRXL is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check LMDX's competition here
DermTech, Inc. (NASDAQ: DMTK)
PRXL vs DMTK Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas DMTK's P/E ratio is -0.04. In terms of profitability, PRXL's ROE is +0.17%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, PRXL is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check DMTK's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
PRXL vs BIAF Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIAF has a market cap of 3.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BIAF trades at $6.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BIAF's P/E ratio is -0.87. In terms of profitability, PRXL's ROE is +0.17%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, PRXL is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BIAF's competition here
Inotiv, Inc. (NASDAQ: NOTV)
PRXL vs NOTV Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NOTV's P/E ratio is -0.03. In terms of profitability, PRXL's ROE is +0.17%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, PRXL is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
PRXL vs SQL Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas SQL's P/E ratio is -0.40. In terms of profitability, PRXL's ROE is +0.17%, compared to SQL's ROE of -30.46%. Regarding short-term risk, PRXL is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
PRXL vs AWH Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas AWH's P/E ratio is -0.09. In terms of profitability, PRXL's ROE is +0.17%, compared to AWH's ROE of +1.62%. Regarding short-term risk, PRXL is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check AWH's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
PRXL vs HTGM Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas HTGM's P/E ratio is -0.03. In terms of profitability, PRXL's ROE is +0.17%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, PRXL is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
PRXL vs BIOC Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BIOC's P/E ratio is -0.01. In terms of profitability, PRXL's ROE is +0.17%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, PRXL is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
PRXL vs SQLLW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, PRXL is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check SQLLW's competition here
iSpecimen Inc. (NASDAQ: ISPC)
PRXL vs ISPC Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, ISPC has a market cap of 165.2K. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while ISPC trades at $1.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas ISPC's P/E ratio is -0.04. In terms of profitability, PRXL's ROE is +0.17%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, PRXL is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check ISPC's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
PRXL vs WGSWW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, PRXL's ROE is +0.17%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, PRXL is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for PRXL.Check WGSWW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
PRXL vs BNGOW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas BNGOW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, PRXL is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check BNGOW's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
PRXL vs NDRAW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas NDRAW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, PRXL is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check NDRAW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
PRXL vs OCDX Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, OCDX has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas OCDX's P/E ratio is -42.28. In terms of profitability, PRXL's ROE is +0.17%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, PRXL is less volatile compared to OCDX. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check OCDX's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
PRXL vs MEUSW Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas MEUSW's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to MEUSW's ROE of -42.03%. Regarding short-term risk, PRXL is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check MEUSW's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
PRXL vs CHEKZ Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, PRXL's ROE is +0.17%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, PRXL is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check CHEKZ's competition here
Danaher Corporation (NYSE: DHR-PA)
PRXL vs DHR-PA Comparison September 2026
PAREXEL Intl Corp. (NASDAQ: PRXL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, PRXL stands at 0. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, PRXL is priced at $88.08 on the NASDAQ, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
PRXL currently has a P/E ratio of 42.97, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, PRXL's ROE is +0.17%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, PRXL is less volatile compared to DHR-PA. This indicates lower risk in terms of short-term price fluctuations for PRXL.Check DHR-PA's competition here